Drug Profile
Belimumab - AstraZeneca/GSK
Alternative Names: Anti-BLyS monoclonal antibody; Benlysta; BmAb; GSK1550188; HGS-1006; LSB; LymphoStat-B; monoclonal anti-BLySLatest Information Update: 19 Dec 2023
Price :
$50
*
At a glance
- Originator Cambridge Antibody Technology; Human Genome Sciences
- Developer Assistance Publique Hopitaux de Paris; Cancer Trials Australia; GlaxoSmithKline; GSK; Hospital for Special Surgery; Human Genome Sciences; National Institute of Allergy and Infectious Diseases; North Shore-Long Island Jewish Health System; University of Pennsylvania; University of Wisconsin-Madison; Washington University School of Medicine
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Urologics
- Mechanism of Action B cell activating factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Lupus nephritis; Systemic lupus erythematosus
- Phase III Anti-neutrophil cytoplasmic antibody-associated vasculitis
- Phase II/III Myositis; Systemic scleroderma
- Phase II Membranous glomerulonephritis; Multiple sclerosis; Myasthenia gravis; Renal transplant rejection
- No development reported Graft-versus-host disease; Waldenstrom's macroglobulinaemia
- Discontinued Rheumatoid arthritis; Sjogren's syndrome
Most Recent Events
- 04 Dec 2023 700361548: Updated KDM, added devlines and HE.
- 13 Sep 2023 Phase-II/III clinical trials in Systemic scleroderma in Denmark, United Kingdom, Spain, Mexico, South Korea, Japan, Italy, Israel, Greece, Germany, France, Finland, China, Canada, Brazil, Belgium, Australia, Argentina, USA (SC) (NCT05878717)
- 01 Feb 2023 GlaxoSmithKline plans a phase II/III trial in Interstitial lung diseases in the first half of 2023 (GlaxoSmithKline pipeline, February 2023)